FDA Approves Biosimilar to Humira – IBD in the News

The FDA recently approved of a biosimilar (CT-P13) to infliximab, which is used for treating IBD patients, as well as patients suffering from rheumatoid arthritis ankylosing spondylitis, psoriatic arthritis, and plaque psoriasis. The new drug would be the first biosimilar monoclonal antibody approved in the United States.

Dr. Edward Loftus, M.D., discusses some of the issues surrounding this medication, and its potential benefits and drawbacks. 


Created by

Mayo Clinic